Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 2Phase 2/3 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Head & Neck 1

Conditions

Prostatic Neoplasms 4Salivary Gland Adenoma, Pleomorphic 1Prostate Adenocarcinoma 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × histrelin × Genitourinary × Clear all
NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 3 Recruiting
1,273 enrolled
Genitourinary

Prostatic Neoplasms

NCT01394263 2024-01-02

Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

Endo Pharmaceuticals

Phase 3 Completed
59 enrolled
Genitourinary

Prostatic Neoplasms

NCT01697384 2024-01-02

Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Endo Pharmaceuticals

Phase 3 Completed
138 enrolled
GenitourinaryHead & Neck

Salivary Gland Adenoma, Pleomorphic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡